1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Damona Pharmaceuticals Inc.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2022

Location

Toronto ON Canada

Primary Industry

Pharmaceuticals

About

Based in Toronto, CA, and founded in 2022, Damona Pharmaceuticals Inc., f.k.a. Alpha Cog, a.k.a. Damona Pharmaceuticals is a pre-clinical pharmaceutical company founded by interim CEO Dr. Etienne Sibille and the Centre for Addiction and Mental Health (CAMH), discovering and developing small molecules for the treatment and prevention of cognitive symptoms in depression and other brain disorders. In September 2022, Damona Pharmaceuticals Inc. raised USD 5.5 million in seed funding co-led by Lumira Ventures and Noetic Fund, with participation from TIAP. The company is developing AC-101, a preclinical stage pharmaceutical product for the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations. Damona Pharmaceuticals plans to use its proceeds from September 2022 funding to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging as well as early-stage development programs.
Current Investors
TIAP, Noetic Fund, Lumira Ventures

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.damonapharma.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.